logo
  

Kimco Realty Q2 FFO Increases; Raises Full Year FFO Guidance - Quick Facts

Kimco Realty Corp. (KIM) reported second quarter net income available to shareholders of $112.4 million, or $0.27 per share, compared to $74.9 million, or $0.18 per share, for the second quarter of 2014. Income from continuing operations decreased to $101.11 million from $128.99 million, a year ago. Income per share from continuing operations was $0.27, flat with previous year.

FFO was $182.7 million, or $0.44 per share compared to $141.2 million, or $0.34 per share, for the second quarter of 2014. FFO as adjusted, which excludes the effects of non-operating impairments as well as transactional income and expenses, was $152.7 million, or $0.37 per share, for the second quarter of 2015.

On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $0.42 for the quarter. Analysts' estimates typically exclude special items.

Total revenues increased to $294.06 million from $245.96 million, a year ago. Analysts expected revenue of $282.20 million for the quarter.

Kimco has increased its 2015 full-year guidance range for FFO and FFO as adjusted. FFO per share is expected to be in the range of $1.52 - $1.56. FFO as adjusted per share is expected to be in the range of $1.43 - $1.46. Analysts expect the company to report earnings per share of $1.54.

Kimco's board declared a quarterly cash dividend of $0.24 per common share, payable on October 15, 2015, to shareholders of record on October 5, 2015, with an ex-dividend date of October 1, 2015. This dividend represents a 6.7% increase over the previous dividend paid for the comparable period in 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT